

## Key Investor Information

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

# Allianz Biotechnologie Share Class R (EUR)



Managed by Allianz Global Investors GmbH, part of Allianz Global Investors

ISIN: DE000A2AMPU5  
WKN: A2AMPU

## Objectives and Investment Policy

The fund seeks to generate capital growth over the long term.

We follow an active management approach with the aim to outperform the Benchmark. We will acquire assets that are constituents of the Benchmark and we may use our discretion to invest in assets not included in the Benchmark. In selecting and weighting the fund's assets we deviate significantly from the Benchmark.

We invest at least 70% of the fund's assets, directly or using derivatives, in shares and equivalent securities of companies whose main activity is in the area of research, development and production of biotech products, processes or services. We can invest up to 10% of the fund's assets in China A-Shares. We can

also invest in other shares and equivalent securities.

Benchmark: NASDAQ Biotechnology Price (in EUR).

We have discretion to deviate from the benchmark.

You may redeem shares of the fund usually on each business day.

We usually distribute the income of the fund on a yearly basis.

Derivatives may be used to offset exposure to price fluctuations (hedging), to take advantage of price differences between two or more markets (arbitrage) or to multiply gains although it may also multiply losses (leverage).

## Risk and Reward Profile



This risk and reward indicator is based on past performance data. It may not be a reliable indication of the future risk profile of the fund.

The categorisation of the fund is not guaranteed and may change in the future.

Even the lowest category 1 does not mean a risk-free investment.

### Why is the fund in this category?

Funds of category 7 have shown in the past a very high volatility. The volatility describes how much the value of the fund went up and down in the past. The units of a fund of category 7 might be subject to very high price fluctuations based on the historical volatilities observed.

## Charges

These charges are used to pay the costs of running the fund, including the costs of marketing and selling. They reduce the potential growth of your investment.

### One-off charges deducted before or after you invest

Entry Charge	0.00%
Exit Charge	0.00%

This is the maximum charge that might be taken out of your money before it is invested or before the proceeds of your investments are paid out.

### Charges taken from the fund over a year


Ongoing Charges	1.16%
-----------------	-------

The entry and exit charges shown are maximum figures. In some cases you might pay less – you can find actual entry and exit charges from your financial adviser.

The ongoing charges shown are based on the fund's last financial year ending 31.12.2021. It may vary from year to year. It does not include transaction costs incurred when we buy or sell assets for the fund.

You will find more details about the calculation of the charges by checking the respective part of the prospectus.

## Past Performance



- Percentage growth of the fund
- Index: NASDAQ Biotechnology Price (in EUR)

Past performance is not a reliable guide to future performance.

The actual grade of deviation from the Benchmark defines the extent to which the fund's performance may outperform or underperform the Benchmark's performance.

The past performance shown here takes account of all charges and costs with the exception of the entry and exit charge.

The fund was launched in 1998.

The performance of the fund is calculated in EUR.

## Practical Information

Depository: State Street Bank International GmbH

You may obtain free of charge the prospectus, the latest annual and semi-annual reports in English and German from Allianz Global Investors GmbH, Bockenheimer Landstraße 42-44, D-60323 Frankfurt/Main or at <https://regulatory.allianzgi.com>.

The unit prices as well as further information on the fund (including other shareclasses of the fund) are available online at <https://regulatory.allianzgi.com>.

Information on the current remuneration policy, including a description of the calculation methods for remuneration and benefits awarded to certain groups of employees, and details of the persons responsible for awarding such allocations, is available at <https://regulatory.allianzgi.com> and as a paper copy upon request, without charge.

The fund is subject to tax laws and regulations in Germany. This might have an impact on your personal tax position. For further details, please speak to your tax advisor.

Allianz Global Investors GmbH may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the fund.

This fund is authorised in Germany and regulated by Bundesanstalt für Finanzdienstleistungsaufsicht. Allianz Global Investors GmbH is authorised in Germany and regulated by Bundesanstalt für Finanzdienstleistungsaufsicht.

The key investor information is accurate as at 13.09.2022.